Skip to main content

Cardiff Oncology, Inc. (CRDF)

NASDAQ: CRDF · Delayed Price · USD
6.60 -0.26 (-3.79%)
Sep 20, 2021 4:00 PM EDT - Market closed
Market Cap271.33M
Revenue (ttm)395,656
Net Income (ttm)-23.05M
Shares Out38.76M
EPS (ttm)-0.68
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume537,161
Open6.61
Previous Close6.86
Day's Range6.47 - 6.86
52-Week Range4.88 - 25.50
Beta1.77
AnalystsBuy
Price Target25.33 (+283.8%)
Est. Earnings DateNov 4, 2021

About CRDF

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zyti...

IndustryBiotechnology
Founded1999
CEOMark Erlander
Employees11
Stock ExchangeNASDAQ
Ticker SymbolCRDF
Full Company Profile

Financial Performance

In 2020, CRDF's revenue was $365,993, an increase of 49.61% compared to the previous year's $244,632. Losses were -$19.31 million, 17.6% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CRDF stock is "Buy." The 12-month stock price forecast is 25.33, which is an increase of 283.79% from the latest price.

Price Target
$25.33
(283.79% upside)
Analyst Consensus: Buy

News

Cardiff Oncology (CRDF) Stock Jumps 7%: Will It Continue to Soar?

Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down ...

6 days ago - Zacks Investment Research

Why Shares of Cardiff Oncology Rose on Monday

An insider buy and positive data may have boosted optimism.

6 days ago - The Motley Fool

Why Are Investors Cheering Cardiff Oncology's New Data In Colorectal Cancer Setting?

Cardiff Oncology Inc (NASDAQ: CRDF) has announced new data from Phase 1b/2 evaluating onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line KRAS-mutated metastatic c...

1 week ago - Benzinga

Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust...

SAN DIEGO, Sept. 8, 2021 /PRNewswire/ --  8 of 19 (42%) patients treated per protocol at the recommended Phase 2 dose (RP2D) of onvansertib 15 mg/m2 who were evaluable for disease response as of the dat...

1 week ago - PRNewsWire

Cardiff Oncology to Present at Upcoming Investor Conferences in September

SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications ...

1 week ago - PRNewsWire

Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on Septe...

SAN DIEGO, Aug. 25, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications ...

3 weeks ago - PRNewsWire

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -13.33% and 4.62%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates

SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications w...

1 month ago - PRNewsWire

Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D.

SAN DIEGO, July 12, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new tre...

2 months ago - PRNewsWire

Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021

SAN DIEGO, July 6, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new trea...

2 months ago - PRNewsWire

Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

Other symbols:CTLTNVCRNVSOCXPKI
2 months ago - Zacks Investment Research

Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes

SAN DIEGO, June 28, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new tre...

2 months ago - PRNewsWire

Smoked! How the Hottest Cannabis Stocks Fared This Week

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues t...

3 months ago - Schaeffers Research

Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors

SAN DIEGO, June 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new tre...

3 months ago - PRNewsWire

Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5...

SAN DIEGO, June 8, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new trea...

3 months ago - PRNewsWire

Are Options Traders Betting on a Big Move in Cardiff Oncology (CRDF) Stock?

Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Cardiff Oncology to Present at the Jefferies Virtual Healthcare Conference

SAN DIEGO, May 20, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new trea...

4 months ago - PRNewsWire

Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 0.00% and -4.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Cardiff Oncology Announces First Quarter 2021 Results and Recent Highlights

SAN DIEGO, May 6, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treat...

4 months ago - PRNewsWire

Strength Seen in Cardiff Oncology (CRDF): Can Its 10.3% Jump Turn into More Strength?

Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

4 months ago - Zacks Investment Research

Rising P/E: An Overlooked Way to Pick 5 Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other symbols:ALYACPRTLQDANBRV
4 months ago - Zacks Investment Research

Let's Take A Look At This Weeks Top Performing Sectors 4/28

Using sector -based investment strategies can help you capitalize on changing business cycles. So far this week the Energy Minerals, Finance, Health services, Transportation, and Commercial Services Sec...

Other symbols:EEIQPHXTIRXYGMZ
4 months ago - Benzinga

Rising P/E: An Overlooked Strategy to Pick Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other symbols:ADBEKNSLNBRVVEEV
5 months ago - Zacks Investment Research

Cardiff Oncology's Onvansertib Shows Durable Response, Progression-Free Survival In Colorectal Cancer Patients

Cardiff Oncology Inc (NASDAQ: CRDF) has announced data from its ongoing Phase 1b/2 trial evaluating onvansertib combined with standard-of-care therapy in second-line KRAS-mutated metastatic colorectal c...

5 months ago - Benzinga